Genetic Aberrations and Survival in Plasma Cell Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2008 Jan 25

PMID 18216867

Citations 128

Authors

R E Tiedemann

N Gonzalez-Paz

R A Kyle

R Santana-Davila

T Price-Troska

S A Van Wier

W J Chng

R P Ketterling

M A Gertz

K Henderson

P R Greipp

A Dispenzieri

M Q Lacy

S V Rajkumar

P L Bergsagel

A K Stewart

R Fonseca

Affiliations

Soon will be listed here.

Abstract

Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM). We report here the genetic aberrations and survival of 80 patients with pPCL or sPCL and make comparisons with 439 cases of MM. pPCL presents a decade earlier than sPCL (54.7 vs 65.3 years) and is associated with longer median overall survival (11.1 vs 1.3 months; P<0.001). 14q32 (IgH) translocations are highly prevalent in both sPCL and pPCL (82-87%); in pPCL IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 16q23 (MAF), recapitulating MM. Both show ubiquitous inactivation of TP53 (pPCL 56%; sPCL 83%) by coding mutation or 17p13 deletion; complemented by p14ARF epigenetic silencing in sPCL (29%). Both show frequent N-RAS or K-RAS mutation. Poor survival in pPCL was predicted by MYC translocation (P=0.006). Survival in sPCL was consistently short. Overall pPCL and sPCL are different disorders with distinct natural histories, genetics and survival.

Citing Articles

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.

Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M Biomark Res. 2024; 12(1):137.

PMID: 39538363 PMC: 11565275. DOI: 10.1186/s40364-024-00676-9.

Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.

Atas U, Salim O, Iltar U, Yucel O, Kucukdiler Eroglu A, Aslan V Turk J Haematol. 2024; 41(4):225-235.

PMID: 39501735 PMC: 11628765. DOI: 10.4274/tjh.galenos.2024.2023.0450.

A Case of Plasma Cell Leukemia Arising De Novo: A Rare and Fatal Disease.

Sweidan H, Jarrah A, Zhu F, Wang Y Cureus. 2024; 16(10):e71393.

PMID: 39403422 PMC: 11471913. DOI: 10.7759/cureus.71393.

[Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].

Deng J, Jin X, Zhang Z, Zhou H, Yang G, Geng C Zhonghua Xue Ye Xue Za Zhi. 2024; 45(7):645-650.

PMID: 39231768 PMC: 11388131. DOI: 10.3760/cma.j.cn121090-20240129-00042.

Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.

Tessier C, LeBlanc R, Roy J, Trudel S, Cote J, Lalancette M Cancer Med. 2024; 13(17):e70192.

PMID: 39225552 PMC: 11369989. DOI: 10.1002/cam4.70192.

References

Hayman S, Bailey R, Jalal S, Ahmann G, Dispenzieri A, Gertz M . Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001; 98(7):2266-8. DOI: 10.1182/blood.v98.7.2266. View

Gertz M, Lacy M, Dispenzieri A, Greipp P, Litzow M, Henderson K . Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005; 106(8):2837-40. PMC: 1895302. DOI: 10.1182/blood-2005-04-1411. View

Kyle R . Multiple myeloma. An update on diagnosis and management. Acta Oncol. 1990; 29(1):1-8. DOI: 10.3109/02841869009089984. View

Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M . Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique.... Blood. 2001; 97(3):822-5. DOI: 10.1182/blood.v97.3.822. View

Oken M, Leong T, LENHARD Jr R, Greipp P, Kay N, Van Ness B . The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer. 1999; 86(6):957-68. View

May P, May E . Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 2000; 18(53):7621-36. DOI: 10.1038/sj.onc.1203285. View

Fonseca R, Harrington D, Oken M, Dewald G, Bailey R, Van Wier S . Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res. 2002; 62(3):715-20. View

Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero M, Blade J, Moro M . Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999; 93(3):1032-7. View

Leslie N, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes C . Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J. 2001; 357(Pt 2):427-35. PMC: 1221969. DOI: 10.1042/0264-6021:3570427. View

10.

Kato S, Han S, Liu W, Otsuka K, Shibata H, Kanamaru R . Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003; 100(14):8424-9. PMC: 166245. DOI: 10.1073/pnas.1431692100. View

11.

Smadja N, Leroux D, Soulier J, Dumont S, Arnould C, Taviaux S . Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer. 2003; 38(3):234-9. DOI: 10.1002/gcc.10275. View

12.

Christou L, Hatzimichael E, Chaidos A, Tsiara S, Bourantas K . Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. Eur J Haematol. 2001; 67(1):51-3. DOI: 10.1034/j.1600-0609.2001.067001051.x. View

13.

Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R . Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol. 2002; 22(11):3842-51. PMC: 133830. DOI: 10.1128/MCB.22.11.3842-3851.2002. View

14.

Ganguly A, Rock M, Prockop D . Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A. 1993; 90(21):10325-9. PMC: 47767. DOI: 10.1073/pnas.90.21.10325. View

15.

Ahuja H, Foti A, Bar-Eli M, Cline M . The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood. 1990; 75(8):1684-90. View

16.

Fonseca R, Debes-Marun C, Picken E, Dewald G, Bryant S, Winkler J . The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003; 102(7):2562-7. DOI: 10.1182/blood-2003-02-0493. View

17.

Stott F, Bates S, James M, McConnell B, Starborg M, Brookes S . The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17(17):5001-14. PMC: 1170828. DOI: 10.1093/emboj/17.17.5001. View

18.

Saez B, Martin-Subero J, Guillen-Grima F, Odero M, Prosper F, Cigudosa J . Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes. Leukemia. 2004; 18(3):654-7. DOI: 10.1038/sj.leu.2403256. View

19.

Fonseca R, Bailey R, Ahmann G, Rajkumar S, Hoyer J, Lust J . Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002; 100(4):1417-24. View

20.

Fonseca R, Hoyer J, Aguayo P, Jalal S, Ahmann G, Rajkumar S . Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk Lymphoma. 1999; 35(5-6):599-605. DOI: 10.1080/10428199909169625. View